S. Dawood, S. D. Merajver, P. Viens, P. B. Vermeulen, S. M. Swain et al., International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment, Ann Oncol, vol.22, pp.515-538, 2011.

M. R. Kell and M. Morrow, Surgical aspects of inflammatory breast cancer, Breast Dis, vol.22, pp.67-73, 2005.

F. M. Robertson, M. Bondy, W. Yang, H. Yamauchi, S. Wiggins et al., Inflammatory breast cancer: the disease, the biology, the treatment, CA Cancer J Clin, vol.60, pp.351-75, 2010.

J. L. Allensworth, M. K. Evans, F. Bertucci, A. J. Aldrich, R. A. Festa et al., Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer, Mol Oncol, vol.9, pp.1155-68, 2015.

M. P. Jansen, L. Sas, A. M. Sieuwerts, C. Van-cauwenberghe, D. Ramirez-ardila et al., Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease, Mol Oncol, vol.9, pp.1218-1251, 2015.

W. A. Woodward, B. G. Debeb, W. Xu, and T. A. Buchholz, Overcoming radiation resistance in inflammatory breast cancer, Cancer, vol.116, pp.2840-2845, 2010.

S. Loibl, C. Denkert, V. Minckwitz, and G. , Neoadjuvant treatment of breast cancer-clinical and research perspective, Breast, vol.24, pp.73-77, 2015.

M. Untch, G. E. Konecny, S. Paepke, V. Minckwitz, and G. , Current and future role of neoadjuvant therapy for breast cancer, Breast, vol.23, pp.526-563, 2014.

M. Kaufmann, G. Von-minckwitz, E. P. Mamounas, D. Cameron, L. A. Carey et al., Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer, Ann Surg Oncol, vol.19, pp.1508-1524, 2012.

P. Cortazar, L. Zhang, M. Untch, K. Mehta, J. P. Costantino et al., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, vol.384, pp.164-72, 2014.

M. Kaufmann, G. N. Hortobagyi, A. Goldhirsch, S. Scholl, A. Makris et al., Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update, J Clin Oncol, vol.24, pp.1940-1949, 2006.

M. Kaufmann, G. Von-minckwitz, H. D. Bear, A. Buzdar, P. Mcgale et al., Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives, Ann Oncol, vol.18, pp.1927-1961, 2006.

G. K. Ellis, W. E. Barlow, J. R. Gralow, G. N. Hortobagyi, C. A. Russell et al., Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily

Z. A. Nahleh, W. E. Barlow, D. F. Hayes, A. F. Schott, J. R. Gralow et al., SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer, Breast Cancer Res Treat, vol.158, pp.485-95, 2016.

L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch et al., Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort, Lancet, vol.375, pp.377-84, 2010.

T. M. Prowell and R. Pazdur, Pathological complete response and accelerated drug approval in early breast cancer, N Engl J Med, vol.366, pp.2438-2479, 2012.

P. Bonnier, C. Charpin, C. Lejeune, R. S. Tubiana, N. Beedassy et al., Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition?, Int J Cancer, vol.62, pp.382-387, 1995.

S. D. Costa, G. Von-minckwitz, G. Raab, J. U. Blohmer, V. Dresel et al., The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer, Semin Oncol, vol.26, pp.24-31, 1999.

M. Cristofanilli, A. U. Buzdar, N. Sneige, T. Smith, B. Wasaff et al., Paclitaxel in the multimodality treatment for inflammatory breast carcinoma, Cancer, vol.92, pp.1775-82, 2001.

P. Viens, T. Palangié, M. Janvier, M. Fabbro, H. Roché et al., First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial), Br J Cancer, vol.81, pp.449-56, 1999.

A. Gonçalves, J. Y. Pierga, J. M. Ferrero, M. A. Mouret-reynier, T. Bachelot et al., UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer, Ann Oncol, vol.26, pp.1692-1699, 2015.

T. Palangie, P. Viens, H. Roche, P. Beuzeboc, V. Dieras et al.,

, Dose-intensified chemotherapy and additional Docetaxel may improve inflammatory breast cancer patients outcome over two decades: results from Institut Curie protocols 1977?_"1987 and two consecutive French multicenter trials Pegase 02 (1995?_"96) and Pegase 05 (1997?_"99), ASCO Annu Meet Proc, vol.22, p.848, 2004.

H. Masuda, T. M. Brewer, D. D. Liu, T. Iwamoto, Y. Shen et al., Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor-and HER2-defined subtypes, Ann Oncol, vol.25, pp.384-91, 2014.

S. Dawood, N. T. Ueno, V. Valero, W. A. Woodward, T. A. Buchholz et al., Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study, Cancer, vol.117, pp.1819-1845, 2011.

W. A. Woodward and T. A. Buchholz, The role of locoregional therapy in inflammatory breast cancer, Semin Oncol, vol.35, pp.78-86, 2008.

J. A. Low, A. W. Berman, S. M. Steinberg, D. N. Danforth, M. E. Lippman et al., Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy, J Clin Oncol, vol.22, pp.4067-74, 2004.

J. M. Matro, T. Li, M. Cristofanilli, M. E. Hughes, R. A. Ottesen et al., Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome, Clin Breast Cancer, vol.15, pp.1-7, 2015.

G. Frasci, D. 'aiuto, G. Comella, P. Thomas, R. Botti et al., Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study, Br J Cancer, vol.95, pp.1005-1017, 2006.

M. Untch, P. A. Fasching, G. E. Konecny, S. Hasmüller, A. Lebeau et al., Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups, J Clin Oncol, vol.29, pp.3351-3358, 2011.

M. Untch, S. Loibl, J. Bischoff, H. Eidtmann, M. Kaufmann et al., Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy, Lancet Oncol, vol.13, pp.135-179, 2012.

V. Minckwitz, G. Schneeweiss, A. Loibl, S. Salat, C. Denkert et al.,

S. Gerber, B. Zahm, D. M. Kümmel, S. Eidtmann, and H. , Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial, Lancet Oncol, vol.15, pp.747-56, 2014.

H. M. Earl, L. Hiller, J. A. Dunn, C. Blenkinsop, L. Grybowicz et al., Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, Lancet Oncol, vol.16, pp.656-66, 2015.

M. Untch, C. Jackisch, A. Schneeweiss, B. Conrad, B. Aktas et al., Nabpaclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, Lancet Oncol, vol.17, pp.345-56, 2016.

L. Gianni, T. Pienkowski, Y. H. Im, L. Roman, L. M. Tseng et al., Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol, vol.13, pp.25-32, 2012.

S. D. Costa, S. Loibl, M. Kaufmann, D. M. Zahm, J. Hilfrich et al., Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data, J Clin Oncol, vol.28, pp.83-91, 2010.

V. Minckwitz, G. Rezai, M. Loibl, S. Fasching, P. A. Huober et al., Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study, J Clin Oncol, vol.28, pp.2015-2038, 2010.

I. A. Jaiyesimi, A. U. Buzdar, and G. Hortobagyi, Inflammatory breast cancer: a review, J Clin Oncol, vol.10, pp.1014-1038, 1992.

F. Bertucci, N. T. Ueno, P. Finetti, P. Vermeulen, A. Lucci et al., Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival, Ann Oncol, vol.25, pp.358-65, 2013.

K. Raghav, J. T. French, N. T. Ueno, X. Lei, S. Krishnamurthy et al., Inflammatory breast cancer: a distinct clinicopathological entity transcending histological distinction, PLoS One, vol.11, p.145534, 2016.

F. Bertucci, P. Finetti, P. Vermeulen, P. Van-dam, L. Dirix et al., Genomic profiling of inflammatory breast cancer: a review, Breast, vol.23, pp.538-583, 2014.

F. Bertucci, P. Finetti, D. Birnbaum, and P. Viens, Gene expression profiling of inflammatory breast cancer, Cancer, vol.116, pp.2783-93, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01612154

M. Cristofanilli, A. Gonzalez-angulo, N. Sneige, S. W. Kau, K. Broglio et al., Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes, J Clin Oncol, vol.23, pp.41-49, 2005.

J. S. Parker, M. Mullins, M. C. Cheang, S. Leung, D. Voduc et al., Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, vol.27, pp.1160-1167, 2009.

A. Goldhirsch, E. P. Winer, A. S. Coates, R. D. Gelber, M. Piccartgebhart et al., Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol, vol.24, pp.2206-2229, 2013.